Methods for preventing cattle reproductive diseases

a technology for preventing cattle and fetuses, applied in the field of methods for preventing fetuses reproductive diseases, can solve the problems of inactivated bvdv vaccines, inability to achieve fetal protection with inactivated bvdv vaccines, and modified-live bvdv vaccines

Inactive Publication Date: 2007-07-26
PFIZER INC +1
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] The present method provides protection to animals such as bovine, in particular, against systemic infection and reproductive disease. The present method provides protection to animals such as pregnant cows against abortion caused by BHV-1 (IBRV) and BVDV and persistent fetal infections caused by BVDV types 1 and 2. The present method also provides protection to animals such as lactating cows and calves nursing pregnant cows against infections caused by BVDV types 1 and 2. The present method also provides protection to breeding age animals, pregnant animals and lactating animals. Thus, the present method provides protection to animals prior to breeding and during gestation. The present method further provides protection to animals with a history of annual vaccinations against infection or disease caused by IBRV, BVDV, PIV3, BRSV, Campylobacter fetus and / or Leptospirae.

Problems solved by technology

Abortion or mummification can result when pregnant cattle become infected especially during the first trimester.
Fetal protection has not been achieved with inactivated BVDV vaccines due to a short duration of immunity and an inefficient cross-type protection (Bolin, Vet. Clin. North Am.
Moreover, the available modified-live BVDV vaccines are not indicated for use in pregnant cattle or calves nursing pregnant cows.
so known. Leptospiral infection of cattle may result in acute fever, agalactia, abortion, or birth of premature and weak infected calves, and may contribute to breeding failures and low concept
ion rates. Infections can be treated with antibiotics, but they may be inapparent in cattle that are not lactating o
r pregnant. In such cattle they establish acute or chronic infection of the kidneys, resulting in urinary shedding of virulent organisms which in turn may infect other animals or their hum
an handlers. Immunity to Leptospira is serovar specific, and although vaccines have been available for many years, most induce only a poor and short-li

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0065] An intensive safety study was conducted to evaluate the safety for administering a Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Modified-Live Virus Vaccine / Leptospira Canicola-Grippotyphosa-Hardjo-Icterohemorrhagia-Pomona Bacterin (Bovi-Shield® 4+L5) formula containing 10-fold dose of the modified live virus (MLV) components to non-vaccinated and vaccinated pregnant cattle. Study animals consisted of 20 non-vaccinated (Treatment Group T1) an 59 previously vaccinated (Treatment Groups T2=14, T3=15, T4=15, and T5=15) crossbred beef heifers ranging from approximately 160 to 220 days of pregnancy. Pre-breeding vaccination history for the vaccinated animals consisted of a dose of Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Modified-Live Virus Vaccine (Bovi-Shield® 4) that was administered to each T3 and T5 animal approximately 150 days prior to breeding and all T2, T3, T4, and T5 animals received a dose of Bovine Rhinotr...

example 2

[0092] A field safety study was conducted to assess the efficacy of the Bovi-Shield® product line. This Example summarizes the interim results through Day 78 of the study. This study compared the safety of administering a Placebo (sterile water diluent) or one of three lots of Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Modified-Live Virus Vaccine / Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (Bovi-Shield® FP 4+L5) to first trimester pregnant, crossbred beef cows that were vaccinated prior to breeding with Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3, Modified Live Virus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (PregGuard™ FP 9).

[0093] On Day 0, blood samples were collected from each animal, and all animals were examined by ultrasound to confirm pregnancy status. On Day 0, an intramuscular (IM) dose of Placebo was administered to each of the 304 control anim...

example 3

[0107] A field safety study was conducted for the Bovi-Shield® product line. This study compared the safety of administering a Placebo (sterile water diluent) or one of three lots of Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Modified-Live Virus Vaccine / Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (Bovi-Shield® 4+L5) to second trimester pregnant, Holstein heifers that were vaccinated prior to breeding with Bovi-Shield® 4+L5. On Day -1, blood samples were collected from each animal, and all animals were examined by rectal palpation to confirm pregnancy status. On Day 0, an intramuscular (IM) dose of Placebo was administered to each of the 238 control animals that were randomly allocated to Treatment Group T1. Each of the 237 animals allotted to the three vaccine treatment groups T2 (n=80), T3 (n=79), and T4 (n=78) received an IM dose of their assigned lot of Bovi-Shield® 4+L5. Each lot of vaccine met all testing requirem...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application is a divisional of U.S. application Ser. No. 10 / 419,661, filed Apr. 21, 2003.FIELD OF THE INVENTION [0002] The present invention relates to methods for safely vaccinating pregnant cows and calves nursing pregnant cows to prevent diseases or disorders, such as abortion caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus Type 3 (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona by administering to the animal an effective amount of a combination vaccine. The methods of the present invention employ a combination vaccine that can be a whole or partial cell inactivated and / or modified live preparation. BACKGROUND OF THE INVENTION [0003] F...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/70C12Q1/68G01N33/53A61K39/245A61K39/295A61P31/04A61P31/12
CPCA61K39/245C12N2710/16734A61K2039/70A61K39/12C12N2770/24334A61K39/0225A61K39/105A61K2039/5254A61K2039/55A61K2039/552A61P15/00A61P15/04A61P15/06A61P31/04A61P31/12A61P31/22C12N2760/18534C12N2760/18634
Inventor ELLSWORTH, MICHAEL A.FICKEN, MARTIN D.FERGEN, BRIAN J.TUCKER, CASSIUS M.
Owner PFIZER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap